PFIZER INC.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
Observational Study to Assess Maternal, Fetal and Infant Outcomes Following Exposure to Rimegepant
- Conditions
- Migraine
- Interventions
- Other: RimegepantOther: Not taking Rimegepant
- First Posted Date
- 2021-09-16
- Last Posted Date
- 2025-04-09
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 780
- Registration Number
- NCT05046613
- Locations
- 🇺🇸
PPD, Morrisville, North Carolina, United States
European Treatment Patterns and Outcomes Associated With First-Line CDK4/6 Inhibition and Hormonal Therapies
- Conditions
- Metastatic Breast Cancer
- Interventions
- Drug: Aromatase inhibitor
- First Posted Date
- 2021-09-14
- Last Posted Date
- 2024-03-27
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1939
- Registration Number
- NCT05043506
- Locations
- 🇸🇪
Örebro University Hospital, Örebro, Sweden
🇩🇪Medizinische Studiengesellschaft NORD-WEST GmbH, Westerstede, Germany
🇩🇪Ruppiner Kliniken GmbH, Neuruppin, Ostprignitz-ruppin, Germany
A Single Dose Study To Test Two Pediatric Forms Of Ritlecitinib Compared With Adult Ritlecitinib In Healthy Adults
- First Posted Date
- 2021-09-10
- Last Posted Date
- 2023-08-21
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 12
- Registration Number
- NCT05040295
- Locations
- 🇺🇸
New Haven Clinical Research Unit, New Haven, Connecticut, United States
High Gastrointestinal Bleed Risk Outcomes in Patients With Non-valvular Atrial Fibrillation (NVAF) in France
- Conditions
- Atrial Fibrillation
- Interventions
- First Posted Date
- 2021-09-09
- Last Posted Date
- 2025-04-16
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1
- Registration Number
- NCT05038228
- Locations
- 🇬🇧
Pfizer Investigator, London, United Kingdom
Investigation of Safety, Tolerability, Immunogenicity and Pharmacokinetics of Single-Dose of PF-06823859 in Japanese Healthy Participants
- First Posted Date
- 2021-09-08
- Last Posted Date
- 2023-12-15
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 13
- Registration Number
- NCT05037409
- Locations
- 🇯🇵
Medical Corporation Shinanokai Shinanozaka Clinic, Shinjuku-ku, Tokyo, Japan
Study to Evaluate the Efficacy, Immunogenicity, and Safety of RSVpreF in Adults.
- Conditions
- Lower Respiratory Tract Illness
- Interventions
- Biological: Placebo
- First Posted Date
- 2021-09-05
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 38567
- Registration Number
- NCT05035212
- Locations
- 🇺🇸
St. Vincent's Birmingham (Pharmacy), Birmingham, Alabama, United States
🇺🇸St. Vincent's Birmingham, Birmingham, Alabama, United States
🇺🇸Medical Affiliated Research Center, Huntsville, Alabama, United States
A Study to Evaluate GBT021601 in Single and Multiple Doses in Healthy Participants
- First Posted Date
- 2021-09-05
- Last Posted Date
- 2023-07-25
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 129
- Registration Number
- NCT05036512
- Locations
- 🇦🇺
Harry Perkins Institute of Medical Research, Nedlands, Western Australia, Australia
🇦🇺Linear Clinical Research, Nedlands, Western Australia, Australia
🇺🇸ICON Early Phase Services, LLC, San Antonio, Texas, United States
Evaluation of the Relative Bioavailability of Bosutinib Capsules Under Fed Condition and Estimation of Food Effect on Orally Administered Bosutinib Capsule
- First Posted Date
- 2021-09-02
- Last Posted Date
- 2022-07-08
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 32
- Registration Number
- NCT05032690
- Locations
- 🇧🇪
Pfizer Clinical Research Unit - Brussels, Brussels, Bruxelles-capitale, Région DE, Belgium
Drug-Drug Interaction Study to Estimate the Effect of PF-07321332/Ritonavir and Ritonavir on Midazolam in Healthy Participants
- Conditions
- Healthy Participants
- Interventions
- First Posted Date
- 2021-09-02
- Last Posted Date
- 2023-10-04
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 12
- Registration Number
- NCT05032950
- Locations
- 🇧🇪
Brussels Clinical Research Unit, Brussels, Bruxelles-capitale, Région DE, Belgium
Korea Comirnaty Post-marketing Surveillance
- Conditions
- COVID-19VaccinesSARS-CoV-2SafetyAdverse Effects
- Interventions
- First Posted Date
- 2021-09-02
- Last Posted Date
- 2025-05-25
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 12000
- Registration Number
- NCT05032976
- Locations
- 🇰🇷
Pfizer Inc, Seoul, Korea, Republic of